In this presentation, Dory Abelman, a PhD candidate at the Princess Margaret Cancer Centre, University of Toronto, assesses the concordance of molecular profiles between cancer cells derived from bone marrow

Dr Betsy O’Donnell, a haematologist at the Dana-Farber Cancer Institute (US), presents the findings from the SKylaRK trial, a phase 2 study in NDMM patients eligible for transplantation, who received

Prof Claire Harrison, a haematologist at Guy’s and St. Thomas’ Hospital in London (UK), presents collaborative efforts involving colleagues and patients to offer pragmatic recommendations for treating patients with myelofibrosis,

Dr Frida Bugge Askeland, associated research doctor and PhD student at the Oslo Myeloma Center in Norway outlined the REMNANT study.

The REMNANT study aims to assess whether addressing MRD

Dr Gabriel Brisou presents preliminary findings on the utilization of axi-cel in the second-line treatment of patients with early R/R LBCL. In France, real-world data encompassing all patients subjected to

Dr Cecilie Blimark, haematologist at the Sahlgrenska University Hospital in Sweden summarized her extensive population-based investigation encompassing symptomatic MM patients from the Swedish Myeloma Registry, ensuring a robust 98% coverage

Dr Margo Aertgeerts from UZ Leuven presented her PhD research in ALL, the most prevalent cancer in the pediatric population. The aetiology of ALL involves the incremental acquisition of mutations

T-ALL represents a highly aggressive haematological malignancy, characterized by an unmet clinical need, particularly in refractory patients or those resistant to standard treatments. Dr Tim Pieters, PhD at Ghent University